Evidence map›Paper›PMID 40407710›Full record

ArticleJournal of cellular and molecular medicine2025

Matrine Inhibits the Wnt3a/β-Catenin Signalling to Attenuate Pressure Overload-Induced Atrial Remodelling and Vulnerability to Atrial Fibrillation.

Guoxin Zhang, Xue Dong, Boxuan Sun, Zijun Zhou, Yinli Xu, Yuting Huang, Shan Meng, Zijun Cao, Nana Qin, Yan Zhu and 2 more

Abstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Guoxin ZhangState Key Laboratory of Frigid Zone Cardiovascular Disease, Department of Cardiovascular Surgery, General Hospital of Northern Theater Command, Shenyang, Liaoning, China.
Xue DongThe Third Outpatient Department, General Hospital of Northern Theater Command, Shenyang, Liaoning, China.
Boxuan SunState Key Laboratory of Frigid Zone Cardiovascular Disease, Department of Cardiovascular Surgery, General Hospital of Northern Theater Command, Shenyang, Liaoning, China.
Zijun ZhouState Key Laboratory of Frigid Zone Cardiovascular Disease, Department of Cardiovascular Surgery, General Hospital of Northern Theater Command, Shenyang, Liaoning, China.
Yinli XuState Key Laboratory of Frigid Zone Cardiovascular Disease, Department of Cardiovascular Surgery, General Hospital of Northern Theater Command, Shenyang, Liaoning, China.
Yuting HuangState Key Laboratory of Frigid Zone Cardiovascular Disease, Department of Cardiovascular Surgery, General Hospital of Northern Theater Command, Shenyang, Liaoning, China.
Shan MengState Key Laboratory of Frigid Zone Cardiovascular Disease, Department of Cardiovascular Surgery, General Hospital of Northern Theater Command, Shenyang, Liaoning, China.
Zijun CaoState Key Laboratory of Frigid Zone Cardiovascular Disease, Department of Cardiovascular Surgery, General Hospital of Northern Theater Command, Shenyang, Liaoning, China.
Nana QinState Key Laboratory of Frigid Zone Cardiovascular Disease, Department of Cardiovascular Surgery, General Hospital of Northern Theater Command, Shenyang, Liaoning, China.
Yan ZhuState Key Laboratory of Frigid Zone Cardiovascular Disease, Department of Cardiovascular Surgery, General Hospital of Northern Theater Command, Shenyang, Liaoning, China.
Liming YuState Key Laboratory of Frigid Zone Cardiovascular Disease, Department of Cardiovascular Surgery, General Hospital of Northern Theater Command, Shenyang, Liaoning, China.ORCID 0000-0001-5953-5016
Huishan WangState Key Laboratory of Frigid Zone Cardiovascular Disease, Department of Cardiovascular Surgery, General Hospital of Northern Theater Command, Shenyang, Liaoning, China.ORCID 0000-0001-6523-7488

Funding

Liaoning Revitalization Talents Program XLYC2203006National Natural Science Foundation of China 82170328Natural Science Foundation of Liaoning Province 2023-MSLH-349Shenyang Science and Technology Project 22-321-33-36
6 · The paper itself

Abstract

Atrial fibrillation (AF) is closely associated with atrial electrical and structural remodelling, yet effective drug strategies remain limited. Matrine (MAT), the active compound in Sophora flavescens, has shown anti-AF effects, but its mechanisms are unclear. This study explored MAT's impact on pressure overload-induced AF using clinical samples, bioinformatics, network pharmacology and murine models, focusing on the canonical Wnt signalling. A murine pressure overload model was established via transverse aortic constriction (TAC) surgery for 4 weeks. Programmed electrical stimulation, langendorff perfusion, echocardiography, Masson's trichrome staining and western blotting were used to evaluate the potential effects and mechanisms of MAT. The results demonstrated that TAC-induced atrial electrical and structural remodelling significantly increased susceptibility to AF in mice while also up-regulated atrial Wnt3a/β-catenin signalling as well as markers for remodelling and inflammation, which were partially supported by clinical samples. MAT dose-dependently mitigated atrial structural and electrical remodelling. Furthermore, MAT intervention inhibited Wnt3a/β-catenin signalling. However, co-administration of SKL2001, a Wnt/β-catenin agonist, counteracted MAT's benefits. The overall findings suggest that MAT treatment may serve as a potential therapeutic approach for inhibiting TAC-induced atrial electrical and structural remodelling by suppressing Wnt3a/β-catenin signalling pathways, thereby reducing susceptibility to AF.

Indexed as

AlkaloidsAtrial FibrillationAtrial Remodelingbeta CateninQuinolizinesWnt3A ProteinWnt Signaling PathwayAnimalsDisease Models, AnimalHeart AtriaHumansMaleMatrinesMiceMice, Inbred C57BLAlkaloidsbeta CateninMatrinesQuinolizinesWnt3A ProteinWnt3a protein, mouseatrial fibrillationatrial remodellingmatrineWnt3aβ‐Catenin

Identifiers

PMID40407710
PMCPMC12101071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.